Edarbi (azilsartan medoxomil) remains expensive because it has no generic equivalent, leaving it as one of the last brand-only blood pressure medications in a drug class where nearly every competitor went generic years ago. The absence of generic competition means the manufacturer sets the price without the downward pressure that typically slashes costs by 80 percent or more. But the deeper question is why no generic has appeared, and the answer involves a mix of market economics, patent strategy, and the peculiar dynamics of how generic drugmakers choose which products to copy.
The Last Brand Standing in a Crowded Field
Edarbi belongs to a class of blood pressure drugs called angiotensin receptor blockers, or ARBs. The class includes well-known names like losartan, valsartan, olmesartan, and irbesartan, all of which lost patent protection years ago and now have multiple cheap generics available. A month’s supply of generic losartan can cost under ten dollars at many pharmacies. Edarbi, by contrast, can run several hundred dollars per month without insurance, and even with coverage the copay often stings. The drug was approved by the FDA in 2011, making it the newest ARB on the market and the last to face the generic clock.
What makes this situation unusual is that ARBs are largely interchangeable for most patients. Guidelines from major cardiology organizations list multiple ARBs as first-line options for high blood pressure, and most patients do fine on whichever one their insurance covers. So when a doctor prescribes Edarbi specifically, the patient ends up paying a premium to stay within a class that already has abundant low-cost options.
Why No Generic Maker Has Stepped In
The simplest explanation for the lack of a generic is that Edarbi’s market share is small. Generic drug manufacturers are businesses, and they prioritize copying drugs that will sell in high volume. Research on FDA generic drug applications shows that drugs with annual sales above $250 million are roughly five times more likely to attract a generic filing than drugs selling under $10 million per year.1PubMed Central. Factors that have an Impact on Abbreviated New Drug Application (ANDA) Submissions Edarbi has never been a blockbuster. It entered a market already crowded with cheaper ARBs, and most insurance formularies steer patients toward established generics. The result is a relatively small pool of Edarbi prescriptions, which makes the investment in developing, manufacturing, and winning approval for a generic copy less attractive.
The regulatory process itself adds another layer. Developing a generic is not as simple as copying a recipe. A manufacturer must file an abbreviated application with the FDA, demonstrate that its version is bioequivalent to the brand, and meet manufacturing standards. When the reference drug involves complex chemistry, the likelihood of a generic application drops further. Azilsartan medoxomil is a prodrug, meaning it must be converted in the body to its active form, and laboratory work has identified multiple distinct impurities that can form during synthesis.2ChemistrySelect. Identification, Synthesis, and Characterization of Novel Impurities of Azilsartan Medoxomil, AT1 Receptor Antagonist Managing those impurities adds cost and technical difficulty to any generic manufacturing effort, and the payoff at the end may not justify the trouble for a low-volume drug.
Does Edarbi Actually Work Better Than Cheaper ARBs?
The clinical case for Edarbi rests on a handful of head-to-head trials suggesting it lowers blood pressure slightly more than some competitors. In a trial of about 1,300 patients with moderate to severe high blood pressure, the 80 mg dose of azilsartan medoxomil produced significantly greater reductions in 24-hour systolic blood pressure compared to both olmesartan and valsartan at their maximum approved doses.3US Cardiology. Azilsartan Medoxomil for Treating Hypertension – Clinical Implications of Recent Trials The 40 mg dose was about equal to olmesartan. These are real differences in ambulatory blood pressure monitoring, which tracks pressure over a full day and is considered a more reliable measure than single office readings.
That said, the difference is modest in absolute terms, typically a few millimeters of mercury. For most people with garden-variety high blood pressure, that gap can be closed by adjusting the dose of a generic ARB or adding a low-cost second medication like a diuretic. The superiority data matters more for patients who are hard to control on existing medications, and even then, cardiologists often reach for combination therapy rather than a premium single agent. The clinical edge, while statistically real, is not the kind of dramatic improvement that makes a drug irreplaceable.
Edarbyclor and the Product Line Extension Problem
Edarbi’s manufacturer also sells Edarbyclor, a combination pill that pairs azilsartan with chlorthalidone, a cheap and widely available diuretic. Combination pills are convenient because patients take one tablet instead of two, but the price difference is dramatic. In 2016, Edarbyclor cost about $5.36 per pill. A generic ARB like losartan prescribed alongside chlorthalidone would have cost roughly $0.94 per pill for the same therapeutic approach. For the roughly 12,000 Medicare beneficiaries who were prescribed Edarbyclor that year, the estimated excess spending was about $11 million.4JAMA. Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents
This pricing strategy is common across the pharmaceutical industry. By combining a brand-name ingredient with a generic one in a single pill, the manufacturer can charge a premium for convenience while extending the commercial life of the brand franchise. Patients and doctors who value the simplicity of one daily pill end up absorbing a cost that is many times higher than what the individual ingredients would cost separately. For Edarbyclor, the azilsartan component is doing essentially all the work of inflating the price, since chlorthalidone has been available as a generic for decades.
How Insurance Formularies Push Back
Most insurance plans and pharmacy benefit managers have responded to Edarbi’s price by placing it on higher formulary tiers or excluding it outright. Beginning around 2012, pharmacy benefit managers started systematically refusing to cover newly approved drugs when cheaper alternatives in the same class were already available.5American Economic Review: Insights. Insurance Design and Pharmaceutical Innovation ARBs are a textbook case for this approach: the class already had multiple generic options, so covering a new, expensive brand-name entry made little financial sense for insurers.
For patients, this creates a frustrating loop. If your doctor believes Edarbi is the right choice for you, your insurance may require prior authorization, demand evidence that you tried and failed on cheaper ARBs first, or simply decline to cover it. Even when coverage is approved, the drug often lands on a specialty or non-preferred tier with a high copay. The formulary restrictions themselves further shrink Edarbi’s market, which in turn makes it even less appealing for generic manufacturers to pursue, reinforcing the cycle that keeps the price elevated.
Copay Cards and Their Limits
Edarbi’s manufacturer offers copay assistance cards, which are common for expensive brand-name drugs. These cards can reduce your out-of-pocket cost at the pharmacy to a much lower amount, sometimes as little as a few dollars per fill. On the surface, this seems like a solution, but it comes with significant catches.
Copay cards are typically available only to patients with commercial insurance, not Medicare or Medicaid. And even for commercially insured patients, many insurers have started implementing copay adjustment programs that exclude manufacturer assistance from counting toward your deductible or annual out-of-pocket maximum. Research on these programs shows they effectively shift costs back to patients over the course of a plan year, with non-White patients disproportionately likely to be affected by such adjustments.6PubMed Central. Assessment of racial and ethnic inequities in copay card utilization and enrollment in copay adjustment programs The copay card covers some of the sticker shock, but it does not eliminate the underlying cost problem, and the benefit can evaporate partway through the year when the card’s annual cap is reached.
Broader research on copay coupons in general has found that they tend to increase insurer costs significantly without delivering equivalent savings to patients, who may face higher premiums or plan costs down the line as a result.7Management Science. Who Benefits When Prescription Drug Manufacturers Offer Copay Coupons? The coupons keep patients on expensive brand-name drugs when cheaper alternatives would work, which raises costs across the insurance pool. Consumer advocacy groups and insurers have pushed to limit or ban these programs for exactly that reason.
What High Costs Mean for Actually Taking the Medication
The practical fallout from Edarbi’s price goes beyond finances. When patients face higher out-of-pocket costs, they are less likely to take their medications consistently. A review of the research literature found that in about 85 percent of the studies examined, increasing patient cost sharing was significantly associated with a drop in adherence to prescribed medications.8PubMed Central. How patient cost-sharing trends affect adherence and outcomes: a literature review The same body of evidence showed that lower adherence was in turn linked to worse health outcomes.
For blood pressure medications, this is a particular concern because hypertension is often called a silent condition. You feel fine until you don’t. Skipping doses or abandoning a prescription because of cost does not produce immediate symptoms, but it raises long-term risks for heart attack, stroke, and kidney disease. If a patient prescribed Edarbi cannot afford it and does not switch to a cheaper ARB, they may simply stop treating their blood pressure altogether. The irony is that any statistical blood-pressure advantage Edarbi offers over generic ARBs is wiped out entirely if the patient cannot afford to take it consistently.
The Broader Pattern of Brand-Name ARB Spending
Edarbi is not an isolated case. An analysis of Medicare Part D spending on blood pressure drugs from 2018 through 2022 found that even as the number of enrollees prescribed an ARB or ACE inhibitor grew by more than 10 percent, overall spending on these drugs stayed roughly flat, largely because generic prices fell. Generic ARB prices dropped by about 13 percent over that period, while brand-name ARB prices barely moved. The study estimated that if every brand-name prescription had been swapped for its generic equivalent, Medicare could have saved about $429 million cumulatively. Going further and switching all prescriptions to the cheapest generic in each class could have saved an estimated $2.66 billion.9The American Journal of Medicine. Brand-names and higher-cost generics drive avoidable Medicare Part D expenditures: A quantitative analysis using ACEis and ARBs as a model
Those numbers put Edarbi’s pricing in context. The drug exists in a class where generic substitution is straightforward, clinically supported, and would save the healthcare system hundreds of millions of dollars. The fact that some patients remain on Edarbi is partly a function of clinical choice, partly physician habit, and partly the influence of pharmaceutical marketing. Research on how drug companies promote brand-name medications to physicians has found that direct outreach to prescribers increases the number of new prescriptions written for the promoted drug, with the effect primarily working by convincing doctors to start patients on the brand rather than by increasing the total number of prescriptions in the class.10Health Economics. Effects of Physician-directed Pharmaceutical Promotion on Prescription Behaviors: Longitudinal Evidence In other words, marketing does not create new patients who need ARBs. It redirects existing patients from generics to the brand.
What the Valsartan Recall Revealed About ARB Markets
In 2018, a global recall of valsartan products due to contamination with a probable carcinogen disrupted the ARB supply chain and offered a natural experiment in how patients and doctors respond when a cheap generic suddenly becomes unavailable. Global valsartan use dropped by roughly 16 percent following the recall, while prescriptions for other ARBs surged by about 45 percent as clinicians moved patients to alternatives. One might expect that some of those displaced patients landed on Edarbi, but the shift primarily benefited other generic ARBs like losartan and irbesartan, which had the manufacturing capacity to absorb the demand.
The recall episode underscored something important about the ARB market: when disruptions happen, the system routes patients toward whatever is cheap and available. Edarbi, with its high price and lack of generic competition, is structurally excluded from being a fallback option for most patients and insurers. It occupies a niche that only remains viable as long as a subset of patients and prescribers specifically seek it out.
Practical Options If You Are Paying Too Much
If you are currently on Edarbi and struggling with the cost, the most straightforward conversation to have with your doctor is whether switching to a generic ARB makes sense. For the majority of patients with high blood pressure, the clinical differences between Edarbi and generic losartan, valsartan, or olmesartan are small enough that switching does not compromise blood pressure control. If your doctor prescribed Edarbi because other ARBs did not work well enough, ask specifically what was tried and at what doses, since some patients were never actually optimized on a generic before being moved to the brand.
If you and your doctor agree that Edarbi is genuinely the best option, check whether the manufacturer’s patient assistance program covers your situation. Patients without insurance or on Medicare who do not qualify for copay cards may be eligible for separate assistance programs that provide the drug at reduced cost or free. Your pharmacist can also check whether any authorized distributor offers a lower cash price, as retail pricing for brand-name drugs can vary substantially between pharmacies.
For patients on Edarbyclor specifically, the savings from switching are even more dramatic. Because the chlorthalidone component is already a dirt-cheap generic, taking a generic ARB plus a separate chlorthalidone tablet accomplishes the same pharmacological goal at a fraction of the combination pill’s price. The only trade-off is taking two pills instead of one, which for most people is a manageable inconvenience compared to the cost difference.